Resolvyx grants Celtic RX-10045 option

Resolvyx Pharmaceuticals Inc. (Cambridge, Mass.) granted Celtic Therapeutics Holdings L.P. (St. Thomas, U.S. Virgin Islands) an exclusive option to license its RX-10045 for all eye indications. Phase ...